Search
Ethinamate
go.drugbank.com/drugs/DB01031ApprovedIllicitWithdrawnLike many such similar medications, the regular use of ethinamate can result in the development of drug tolerance in a patient.
AN-9
go.drugbank.com/drugs/DB05103InvestigationalPivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. … greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties than BA in
Synonyms: AN-9Liposomal prostaglandin E1
go.drugbank.com/drugs/DB05391InvestigationalLiposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. … The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve.
Synonyms: Liposomal prostaglandin E1TRGFT-201
go.drugbank.com/drugs/DB23064ApprovedInvestigational[L64070,L64071] This composition is designed to improve survival free of chronic GVHD compared with a conventional transplant. … [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic
Higenamine
go.drugbank.com/drugs/DB12779InvestigationalHigenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects).
Categories: Compounds used in a research, industrial, or household settingXL820
go.drugbank.com/drugs/DB05146InvestigationalXL820 is investigated for use/treatment in solid tumors. XL820 is a solid. … XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia.
Ambenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnIt is used in the management of myasthenia gravis.
Friulimicin B
go.drugbank.com/drugs/DB06087InvestigationalIt shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community.
CHF 4227
go.drugbank.com/drugs/DB05882ExperimentalThe compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.